Skip to main content

Table 1 Demographics and Clinical Information

From: Regional cortical thinning in young adults with schizophrenia but not psychotic or non-psychotic bipolar I disorder

Characteristics CON (n = 40) SCZ (n = 52) PBD (n = 49) NPBD (n = 24)
Mean age (SD) 24.9 (5.0) 26.1 (4.1) 25.3 (3.7) 26.2 (3.7)
Sex (%)
 Male 20 (50.0) 38 (73.1) 20 (40.8) 8 (33.3)
 Female 20 (50.0) 14 (26.9) 29 (59.2) 16 (66.7)
Race (%)
 Asian 2 (5.0) 0 1 (2.0) 2 (8.3)
 Black 20 (50.0) 27 (51.9) 13 (26.5) 2 (8.3)
 Hispanic 0 0 3 (6.1) 0
 White 18 (45.0) 25 (48.1) 30 (61.2) 18 (75.0)
 Multiracial 0 0 2 (4.1) 2 (8.3)
Handedness (%)
 Left 4 (10.0) 2 (3.8) 4 (8.2) 3 (12.5)
 Right 36 (90.0) 50 (96.2) 45 (91.8) 21 (87.5)
History of use disorder (%)a
 Alcohol 4 (10.0) 17 (32.7) 23 (46.9) 12 (50.0)
 Cannabis 0 21 (40.4) 17 (34.7) 6 (25.0)
 Stimulant 1 (2.5) 1 (1.9) 1 (2.0) 0
 Opioid 0 1 (1.9) 2 (4.1) 0
 Cocaine 0 0 6 (12.2) 1 (4.2)
 Hallucinogen 0 0 2 (4.1) 1 (4.2)
Psychotropic medication (%)
 Typical antipsychotic 0 8 (13.6) 3 (6.1) 0
 Atypical antipsychotic 0 37 (72.5) 30 (62.2) 6 (25.0)
 SSRI 0 15 (29.4) 24 (49.0) 10 (41.7)
 Other antidepressantsb 0 3 (5.8) 12 (24.5) 7 (29.2)
 Stimulant 0 0 4 (8.2) 3 (12.5)
 Mood stabilizer 0 11 (21.6) 33 (67.3) 18 (75.0)
 Benzodiazepines 0 1 (2.0) 20 (40.8) 6 (25.0)
 Anticholinergic 0 0 8 (16.3) 2 (8.3)
 None 40 (100.0) 13 (25.5) 6 (12.2) 1 (4.2)
Symptom domains (SD)     
 SAPSc 0.25 (.2) 3.56 (3.0) 1.35 (1.9) 0.42 (0.8)
 Hallucination subscale 0 1.40 (1.8) 0.39 (0.9) 0
 Delusion subscale 0.05 (.221) 2.12 (1.4) 0.96 (1.3) 0.42 (0.8)
 SANSd 2.30 (2.3) 10.25 (3.9) 3.18 (3.8) 3.42 (2.4)
 Flat Affect subscale 0.08 (0.4) 1.85 (1.3) 0.59 (0.9) 0.71 (1.2)
 Alogia subscale 0.05 (0.3) 1.23 (1.8) 0.16 (0.5) 0.13 (0.4)
 Anhedonia subscale 0.38 (0.8) 2.48 (1.1) 1.31 (1.4) 1.04 (1.1)
 Amotivation subscale 0.73 (1.1) 3.02 (1.0) 1.24 (1.4) 0.92 (1.2)
 Attention subscale 1.08 (1.3) 1.67 (1.3) 0.88 (1.1) 0.63 (1.0)
  1. aOther than for nicotine use disorder, participants did not meet criteria for a use disorder in the last 6 months
  2. bRefers to antidepressants other than selective serotonin reuptake inhibitors (SSRI)
  3. cMaximum possible score on the Structured Assessment of Positive Symptoms (SAPS) is 16
  4. dMaximum possible score on the Structured Assessment of Negative Symptoms (SANS) is 20